Perry Jennifer Scott 4

What Happened

• Perry Jennifer Scott, Chief Operating Officer of Bicycle Therapeutics plc (BCYC), was granted 60,000 derivative securities (an equity award/option) on July 15, 2026. The Form 4 records an acquisition price of $0.00 per share, so no cash was paid at grant and the immediate reported value on the filing is $0.
• This is a compensation grant (neither an open-market purchase nor a sale) and should be viewed as an awarded equity interest subject to vesting, not an immediate transfer of unrestricted shares.

Key Details

• Transaction date: July 15, 2026; Form 4 filed July 17, 2026 (timely filing).
• Amount granted: 60,000 derivative shares/options; reported acquisition price $0.00 per share.
• Shares owned after transaction: not specified in the summary provided (check the full Form 4 for post-transaction beneficial ownership).
• Vesting note (from filing): 1/4 of the option vests on July 15, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter (i.e., standard 1-year cliff then monthly vesting over 3 years).
• No indication in this filing of a cashless exercise, sale, tax-withholding, or 10b5-1 plan.

Context

• This is a typical equity compensation award to an executive. Because it is a derivative grant with a vesting schedule, the award represents potential future ownership if vesting and any exercise conditions are met — it is not the same as an immediate purchase of stock.
• Retail investors should note that grants are common for executive compensation and do not by themselves signal a buy or sell decision; purchases (out-of-pocket buys) tend to be more directly informative of an insider’s market view.